Clinical Trial

Early PP Monitored by EIT in Patients With ARDS

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Acute Respiratory Distress Syndrome (ARDS) is a syndrome characterized by respiratory distress and refractory hypoxemia caused by pulmonary and extra-pulmonary factors. Despite improvements in diagnosis and treatment in recent years, the mortality rate of severe ARDS is still around 40%. The distribution of lung lesions in ARDS patients is significantly gravity-dependent. Even with lung-protective ventilation strategies, tidal volume is concentrated in the ventral lung region, leading to ventilator-associated lung injury. Prone position ventilation can increase ventilation to the dorsal lung tissue and improve the ventilation-perfusion ratio, thus improving oxygenation. During prone position ventilation in ARDS patients, lung-protective ventilation strategies should be maintained, but with different respiratory mechanics from the supine position, requiring adjustment of ventilator parameters. Electrical Impedance Tomography (EIT) technology can be used for bedside monitoring of mechanically ventilated patients, providing real-time feedback on the patient's ventilation status and having great potential for clinical applications. Investigators believes that EIT monitoring during prone position ventilation in ARDS patients can individualize lung-protective ventilation strategies, minimize alveolar overdistension and collapse, improve the weaning success rate of invasive ventilation, and ultimately improve patient prognosis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-10; most recent amendment 2025-06-13.
Status change: Not Yet Recruiting → Recruiting 2023-07-10
Trial Details
NCT Number NCT05822869
Lead Sponsor Beijing Chao Yang Hospital
Conditions Acute Respiratory Distress Syndrome
Enrollment 60 participants
Start Date 2023-05-01
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-17